New hope for rare leukemia: targeted combo aims to boost survival
NCT ID NCT06991920
First seen Feb 12, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This study tests a new treatment for adults with a rare leukemia called acute leukemia of ambiguous lineage (ALAL). The treatment combines targeted drugs (blinatumomab, venetoclax, and possibly TKI drugs) with standard chemotherapy. The goal is to see if this approach improves survival and remission rates. About 50 participants aged 14 and older will take part across multiple hospitals in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.